Skip to Content
GLP-1s news item 3

New report explores public health and equality implications of GLP-1s

18 Nov 2026

A new GCPH report published today examines the rapidly expanding use of GLP-1 obesity medications, including Mounjaro and Wegovy. The report explores the potential of these medications to improve outcomes for people living with obesity, while considering the implications for population health and health inequalities. It highlights the need to consider how access, affordability and uptake may vary across different groups, and what this could mean for health inequalities in Scotland.

Exploring the public health and equalities implications of GLP-1 obesity medications is an evidence-based discussion paper that draws on 174 sources to examines ten key questions relating to clinical effectiveness, safety, health inequalities, and the wider implications of these medications for population health and public health policy in Scotland.

Key findings of the report include:

  • Significant clinical benefits: GLP-1 medications can achieve substantial weight loss among people living with obesity, typically 5–15% and sometimes approaching 20%, alongside improvements in metabolic and cardiovascular health.
  • Potential to widen health inequalities: Differences in health literacy and access to healthcare may influence who benefits from new NHS obesity treatments. Given that obesity is more prevalent in more deprived communities, there is a risk that existing health inequalities could widen if access to and uptake of GLP-1 medications are not experienced equitably. The availability of these medications through private and online providers may further increase inequalities if affordability becomes a key determinant of access.
  • Safety and unregulated access: While authorised medications are generally well tolerated, side effects, nutritional concerns and emerging longer-term risks require monitoring. Counterfeit products and unregulated online supply present additional significant safety concerns.
  • Weight regain and obesity stigma: Weight regain following treatment discontinuation is common, reinforcing the need to understand obesity as a complex, chronic condition. Stigmatising attitudes risk distorting how treatment effectiveness and sustainability are judged.
  • Integration with health improvement: Evidence increasingly supports combining GLP-1 treatment with nutritional, physical activity and behavioural support, alongside continued investment in prevention and action on the wider determinants of obesity.
  • Further research is essential: Important uncertainties remain around long-term effectiveness, side effects, affordability, cost-effectiveness and wider population health impacts.

Report author Chris Harkins, Public Health Programme Manager at GCPH, said:

"GLP-1 medications represent a major advance in obesity treatment, but realising their full public health potential requires equitable access and integration with wider health improvement approaches, including nutritional and physical activity support.

"We must also challenge the stigma surrounding obesity and medication-assisted weight loss. These treatments are sometimes dismissed as a 'quick fix', while weight regain following discontinuation is viewed as failure, rather than reflecting the complex, chronic nature of obesity."

An opportunity for Scotland to lead

The report calls for equitable implementation, stronger monitoring of treatment access and outcomes, and further research into long-term safety, cost-effectiveness and wider health system impacts.

It concludes that Scotland's established commitment to prevention, reducing health inequalities and improving population health provides a strong foundation for a proactive, integrated approach.

Chris Harkins added:

"Scotland has an opportunity to lead in how we respond to one of our longest-standing public health challenges. By combining this significant clinical advance with our established strengths in prevention, health improvement and tackling inequalities, we have the potential to deliver meaningful, lasting and more equitable improvements in population health."

 Dr Jennifer McLean, Interim Director at GCPH, said:

"GLP-1 medications are generating considerable interest across healthcare, policy and the wider public. While much attention has focused on their potential to improve health outcomes, it is equally important to understand their broader implications for population health. At GCPH, we are committed to bringing an evidence-informed and balanced perspective to this emerging area".

"As use of these medications grows, there is a timely opportunity to explore both their potential benefits and the challenges they may present. Understanding who is able to access and benefit from these treatments, who may be excluded, and how wider impacts are distributed across society is critical. This knowledge can help ensure that policy and practice maximise benefits, reduce inequalities and support better health for all."

arrow left Previous

Where is the data? Accountability, suicide rates and race

Back to

News & Blogs